Relmada Therapeutics (RLMD) Short Interest Ratio & Short Volume $0.68 +0.01 (+2.06%) Closing price 03:59 PM EasternExtended Trading$0.67 -0.01 (-0.74%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Relmada Therapeutics Short Interest DataRelmada Therapeutics (RLMD) has a short interest of 401,300 shares, representing 1.52% of the float (the number of shares available for trading by the public). This marks a -5.33% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 1.11 million shares to cover all short positions.Current Short Interest401,300 sharesPrevious Short Interest423,900 sharesChange Vs. Previous Month-5.33%Dollar Volume Sold Short$249.77 thousandShort Interest Ratio0.9 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares33,190,000 sharesShort Percent of Float1.52%Today's Trading Volume313,640 sharesAverage Trading Volume1,114,167 sharesToday's Volume Vs. Average28% Short Selling Relmada Therapeutics? Sign up to receive the latest short interest report for Relmada Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRLMD Short Interest Over TimeRLMD Days to Cover Over TimeRLMD Percentage of Float Shorted Over Time Relmada Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025401,300 shares $249.77 thousand -5.3%1.5%0.9 $0.62 7/15/2025423,900 shares $267.90 thousand -28.8%N/A0.2 $0.63 6/30/2025595,000 shares $357.18 thousand -14.5%2.3%0.3 $0.60 6/15/2025695,500 shares $486.99 thousand -38.5%2.6%0.4 $0.70 5/31/20251,130,000 shares $814.05 thousand -7.4%4.6%0.6 $0.72 5/15/20251,220,000 shares $504.35 thousand -39.9%4.9%0.7 $0.41 4/30/20252,030,000 shares $654.47 thousand +44.0%N/A1 $0.32 4/15/20251,410,000 shares $434.28 thousand -13.0%5.7%0.8 $0.31 3/31/20251,620,000 shares $437.40 thousand +8.7%6.5%1.7 $0.27 3/15/20251,490,000 shares $436.12 thousand +18.3%6.0%1.4 $0.29 Get the Latest News and Ratings for RLMD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/20251,260,000 shares $327.60 thousand -28.0%5.1%0.8 $0.26 2/15/20251,750,000 shares $582.58 thousand +108.8%7.1%1.1 $0.33 1/31/2025838,000 shares $292.46 thousand -33.0%N/A0.6 $0.35 1/15/20251,250,000 shares $495.63 thousand -24.2%N/A1.3 $0.40 12/31/20241,650,000 shares $858 thousand -7.3%N/A1.7 $0.52 12/15/20241,780,000 shares $653.26 thousand +67.9%N/A2.3 $0.37 11/30/20241,060,000 shares $3.20 million -7.8%N/A1.6 $3.02 11/15/20241,150,000 shares $3.46 million -3.4%N/A6.1 $3.01 10/31/20241,190,000 shares $4.14 million -5.6%N/A6.7 $3.48 10/15/20241,260,000 shares $4.38 million +0.8%N/A6.9 $3.48 9/30/20241,250,000 shares $4.05 million +5.9%N/A6.6 $3.24 9/15/20241,180,000 shares $3.65 million -2.5%N/A6.6 $3.09 8/31/20241,210,000 shares $3.39 million -6.2%N/A10.8 $2.80 8/15/20241,290,000 shares $3.32 million -3.0%N/A11.5 $2.57 7/31/20241,330,000 shares $4.87 million -2.2%N/A12.2 $3.66 7/15/20241,360,000 shares $5.22 million +34.7%N/A13.1 $3.84 6/30/20241,010,000 shares $3.03 million -34.8%N/A9.6 $3.00 6/15/20241,550,000 shares $4.67 million +0.7%N/A14.9 $3.01 5/31/20241,540,000 shares $4.62 million -1.9%N/A11.1 $3.00 5/15/20241,570,000 shares $5.46 million -4.3%N/A10.6 $3.48 4/30/20241,640,000 shares $5.97 million -4.1%N/A9.4 $3.64 4/15/20241,710,000 shares $7.61 million +1.2%N/A8.1 $4.45 3/31/20241,690,000 shares $7.86 million -3.4%N/A7.4 $4.65 3/15/20241,750,000 shares $9.49 million No ChangeN/A5.4 $5.42 2/29/20241,750,000 shares $10.72 million +1.2%N/A5.5 $6.13 2/15/20241,730,000 shares $9.12 million +7.5%N/A5.6 $5.27 1/31/20241,610,000 shares $6.33 million +3.2%N/A5.6 $3.93 1/15/20241,560,000 shares $4.90 million +92.4%N/A6.3 $3.14 12/31/2023810,700 shares $3.36 million +26.9%N/A3.3 $4.14 12/15/2023638,800 shares $1.58 million -26.2%N/A3.7 $2.48Everyone’s watching Nvidia right now. Here’s why I’m excited. (Ad)So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.🎯 Click here to watch the video and get the free ticker XGPT just flagged. 11/30/2023865,800 shares $2.14 million -1.1%N/A5.3 $2.47 11/15/2023875,200 shares $2.65 million +10.1%N/A5.6 $3.03 10/31/2023794,700 shares $2.38 million +13.4%N/A5 $2.99 10/15/2023700,900 shares $2.17 million -2.5%N/A4.6 $3.10 9/30/2023718,700 shares $2.16 million +6.1%N/A4.9 $3.00 9/15/2023677,500 shares $2.09 million +9.7%N/A4.5 $3.09 8/31/2023617,700 shares $2.09 million -10.5%N/A3.8 $3.38 8/15/2023689,800 shares $2.35 million -18.8%N/A4.1 $3.41 7/31/2023849,900 shares $2.23 million -11.0%N/A4.8 $2.62 7/15/2023954,400 shares $2.71 million -9.1%N/A5 $2.84 6/30/20231,050,000 shares $2.58 million -46.7%N/A5.2 $2.46 6/15/20231,970,000 shares $5.02 million -5.3%N/A8.7 $2.55 5/31/20232,080,000 shares $5.91 million +16.9%N/A11.3 $2.84 5/15/20231,780,000 shares $5.50 million -3.3%N/A9.1 $3.09 4/30/20231,840,000 shares $4.64 million +0.6%N/A9.1 $2.52 4/15/20231,830,000 shares $4.96 million +4.0%N/A8.5 $2.71 3/31/20231,760,000 shares $3.98 million +13.6%N/A6.6 $2.26 3/15/20231,550,000 shares $3.97 million +6.2%N/A5 $2.56 2/28/20231,460,000 shares $5.26 million -8.8%N/A2.5 $3.60 2/15/20231,600,000 shares $5.94 million No ChangeN/A2.5 $3.71 1/31/20231,600,000 shares $6.50 million -20.4%N/A2.2 $4.06 1/15/20232,010,000 shares $8.28 million +12.3%N/A2.4 $4.12 12/30/20221,790,000 shares $6.25 million +4.1%N/A1.4 $3.49 12/15/20221,720,000 shares $5.40 million -13.6%N/A1.3 $3.14 11/30/20221,990,000 shares $9.25 million -28.2%N/A1.6 $4.65 11/15/20222,770,000 shares $16.32 million -4.2%N/A2.6 $5.89 10/31/20222,890,000 shares $18.47 million -13.7%N/A2.9 $6.39 10/15/20223,350,000 shares $20.77 million -26.2%N/A3.8 $6.20 9/30/20224,540,000 shares $168.07 million +25.1%N/A12.3 $37.02 9/15/20223,630,000 shares $124.84 million +11.7%N/A11.3 $34.39 8/31/20223,250,000 shares $94.71 million +3.2%N/A11.9 $29.14 8/15/20223,150,000 shares $91.79 million +1.0%N/A12.3 $29.14 7/31/20223,120,000 shares $79.87 million +1.0%N/A12.1 $25.60 7/15/20223,090,000 shares $69.43 million -4.9%N/A11.7 $22.47 6/30/20223,250,000 shares $61.72 million +21.7%N/A12 $18.99 6/15/20222,670,000 shares $44.59 million +1.1%N/A9.5 $16.70 5/31/20222,640,000 shares $49.61 million +21.1%N/A9.2 $18.79 5/15/20222,180,000 shares $43.16 million +32.9%N/A6.6 $19.80 4/30/20221,640,000 shares $41.18 million -4.7%N/A5.1 $25.11 4/15/20221,720,000 shares $44.77 million -4.4%N/A5.5 $26.03 3/31/20221,800,000 shares $48.58 million +23.3%N/A5.9 $26.99 3/15/20221,460,000 shares $32.49 million -11.0%N/A5.2 $22.25 2/28/20221,640,000 shares $33.64 million +34.4%N/A5.9 $20.51 2/15/20221,220,000 shares $24.40 million -8.3%N/A5.1 $20.00 1/31/20221,330,000 shares $24.46 million -21.3%N/A6.6 $18.39 1/15/20221,690,000 shares $33.56 million +24.3%10.7%10 $19.86 12/31/20211,360,000 shares $30.64 million +40.7%8.6%8.6 $22.53 12/15/2021966,900 shares $19.51 million +7.7%6.1%7.1 $20.18 11/30/2021897,600 shares $16.03 million +2.9%5.7%8.2 $17.86 11/15/2021872,400 shares $19.79 million -2.8%5.5%9.2 $22.69Everyone’s watching Nvidia right now. Here’s why I’m excited. (Ad)So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.🎯 Click here to watch the video and get the free ticker XGPT just flagged. 10/29/2021897,500 shares $21.06 million -5.9%5.7%8.2 $23.47 10/15/2021953,300 shares $22.53 million -4.3%6.1%4.1 $23.63 9/30/2021996,200 shares $26.11 million -2.3%6.3%4.1 $26.21 9/15/20211,020,000 shares $27.31 million -1.0%6.5%4.2 $26.77 8/31/20211,030,000 shares $24.63 million +12.1%6.6%4.4 $23.91 8/13/2021918,600 shares $20.99 million +30.5%5.9%3.9 $22.85 7/30/2021704,000 shares $18.30 million -11.9%4.3%3.1 $26.00 7/15/2021798,800 shares $25.20 million -11.7%4.9%8.1 $31.55 6/30/2021904,100 shares $28.94 million -6.5%5.5%10.1 $32.01 6/15/2021966,400 shares $30.92 million -6.2%5.9%11.3 $32.00 5/28/20211,030,000 shares $35.63 million +13.8%6.3%12.5 $34.59 5/14/2021904,800 shares $30.31 million +6.6%5.5%12.2 $33.50 4/30/2021849,000 shares $32.97 million -1.7%5.5%12.9 $38.83 4/15/2021863,500 shares $31.95 million +6.4%5.6%12 $37.00 3/31/2021811,600 shares $28.35 million +13.9%5.3%11.1 $34.93 3/15/2021712,800 shares $26.14 million -8.3%4.8%9.1 $36.67 2/26/2021777,600 shares $26.31 million -12.4%5.2%10 $33.84 2/12/2021887,200 shares $31.97 million -4.8%6.0%11.5 $36.03 1/29/2021931,800 shares $30.39 million -4.3%6.3%12.3 $32.61 1/15/2021974,000 shares $36.64 million +5.6%6.5%11.6 $37.62 12/31/2020922,000 shares $29.04 million +4.0%6.2%9.9 $31.50 12/15/2020886,600 shares $29.78 million -10.2%6.0%9.4 $33.59 11/30/2020987,300 shares $35.53 million -2.3%6.6%10.6 $35.99 11/15/20201,010,000 shares $32.90 million +1.1%6.8%10.9 $32.57 10/30/2020998,600 shares $31.12 million -18.8%6.8%10.9 $31.16 10/15/20201,230,000 shares $44.72 million -30.5%8.4%14.4 $36.36 RLMD Short Interest - Frequently Asked Questions What is Relmada Therapeutics' current short interest? Short interest is the volume of Relmada Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 401,300 shares of RLMD short. 1.52% of Relmada Therapeutics' shares are currently sold short. Learn More on Relmada Therapeutics' current short interest. What is a good short interest ratio for Relmada Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RLMD shares currently have a short interest ratio of 1.0. Learn More on Relmada Therapeutics's short interest ratio. What is a good short interest percentage for Relmada Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.52% of Relmada Therapeutics' floating shares are currently sold short. Is Relmada Therapeutics' short interest increasing or decreasing? Relmada Therapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 401,300 shares, a decrease of 5.3% from the previous total of 423,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Relmada Therapeutics' short interest compare to its competitors? 1.52% of Relmada Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Relmada Therapeutics: Alto Neuroscience, Inc. (10.00%), Oramed Pharmaceuticals Inc. (1.20%), Invivyd, Inc. (4.37%), Vaxart, Inc. (3.62%), Celularity, Inc. (11.50%), Elutia Inc. (0.09%), BeyondSpring Inc. (7.37%), PMV Pharmaceuticals, Inc. (1.84%), Adagene Inc. Sponsored ADR (0.16%), Oncobiologics, Inc. (8.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Relmada Therapeutics stock? Short selling RLMD is an investing strategy that aims to generate trading profit from Relmada Therapeutics as its price is falling. RLMD shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Relmada Therapeutics? A short squeeze for Relmada Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RLMD, which in turn drives the price of the stock up even further. How often is Relmada Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RLMD, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Alto Neuroscience Short Interest Oramed Pharmaceuticals Short Interest Invivyd Short Interest Vaxart Short Interest Celularity Short Interest Elutia Short Interest BeyondSpring Short Interest PMV Pharmaceuticals Short Interest Adagene Short Interest Oncobiologics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RLMD) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access